Natco Pharma Limited has announced a board meeting scheduled for February 12, 2026, to deliberate on key financial matters for the third quarter of fiscal year 2026. The pharmaceutical company informed stock exchanges about the upcoming meeting through an official communication dated January 28, 2026.

Board Meeting Agenda

The board meeting will address two primary items of business that are crucial for shareholders and market participants:

The meeting represents a significant milestone as the company prepares to disclose its third-quarter performance and evaluate the possibility of distributing additional returns to shareholders through an interim dividend.

Trading Window Restrictions

In adherence to SEBI (Prohibition of Insider Trading) Regulations, 2015, Natco Pharma has implemented mandatory trading restrictions. The trading window for company securities will remain closed from January 29, 2026 to February 14, 2026, both days inclusive.

This restriction applies to all employees, connected persons, and their immediate relatives, ensuring compliance with insider trading prevention measures during the period leading up to and following the financial results announcement.

Regulatory Compliance

The board meeting notice has been submitted under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, demonstrating the company's commitment to transparent corporate governance. The communication was signed by Chekuri Venkat Ramesh, Company Secretary and Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Ltd.

The company trades on BSE under scrip code 524816 and on NSE under the symbol NATCOPHARM. Natco Pharma is headquartered at 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad, Telangana, and operates under CIN L24230TG1981PLC003201.

Natco Pharma has provided an official clarification to BSE regarding the ongoing patent litigation with Novo Nordisk over semaglutide, following a stock exchange query about recent news coverage of the legal proceedings.

BSE Query and Company Response

The company responded to BSE's inquiry dated January 7, 2026, addressing questions about the patent dispute proceedings and their potential impact. The pharmaceutical company clarified that the litigation has been continuing for several months with the outcome still awaiting judicial determination.

Patent Dispute Background

The legal proceedings center around Natco Pharma's petition to revoke Novo Nordisk's semaglutide patent. The High Court had previously issued a notice to the Danish pharmaceutical giant, marking a significant development in the patent challenge. Semaglutide is a medication primarily used for treating diabetes and weight management.

Regulatory Compliance Statement

Natco Pharma emphasized its commitment to regulatory compliance, stating that the company has been consistently making disclosures to stock exchanges as required under Regulation 30 of the SEBI (LODR) Regulations, 2015. The company assured continued adherence to these regulations.

Current Status and Future Disclosures

The company indicated that upon the outcome of the litigation, it will inform the stock exchanges in due course based on the material impact of the litigation on the financial performance of the company. As of the current date, the company reports no material financial impact from the ongoing legal proceedings.

The clarification was signed by Ch. Venkat Ramesh, Company Secretary and Compliance Officer, reinforcing the company's transparent approach to stakeholder communication regarding significant legal developments.